Crown Organogenesis Protocols Inc. Calls for Strategic Investors to Scale Agaris™ Plant Biotechnology Platform
Tanza, Cavite, Philippines — Crown Organogenesis Protocols Inc. (COPI), a Philippine-based plant biotechnology company, today announced its call for strategic investors to accelerate the national and international expansion of its proprietary Agaris™ Plant Biotechnology Platform, a Lab-to-Land™ clonal propagation system for high-value agroforestry and perfumery crops.
The Agaris™ platform integrates advanced organogenesis-based tissue culture, greenhouse acclimatization, pathogen indexing, and digital traceability systems to deliver genetically uniform, disease-indexed, and field-ready elite plantlets for commercial plantations.
Addressing a Critical Gap in Plantation Agriculture
Global demand for essential oils, premium spices, and sustainable agroforestry products continues to rise. However, many plantations still rely on seed-grown or unverified planting materials, resulting in inconsistent yields and high mortality rates.
COPI’s Agaris™ system addresses this gap by offering:
- ≥95% genetic uniformity
- 85–95% field survival rates
- Batch-level pathogen screening
- Standardized growth and yield predictability
- Traceable production history from mother tree to field
Strategic Expansion Plan
COPI is seeking strategic growth capital to scale operations across three major phases:
Phase 1 – Infrastructure Expansion
- Commercial-scale tissue culture laboratory development
- Expanded greenhouse hardening facilities
- Increased annual production capacity to 500,000+ plantlets
Phase 2 – Regional Plantation Partnerships
- Estate-level joint ventures (100–1,000 hectares)
- Government and ESG-aligned agroforestry collaborations
- Export-focused spice and essential oil supply chains
Phase 3 – International Licensing & Technology Transfer
- Regional propagation hubs
- Licensing of Agaris™ Lab-to-Land™ protocols
- ASEAN and Middle East strategic partnerships
Capital Raise Objective
COPI is currently raising PHP 50M–150M in strategic growth capital to fund laboratory expansion, greenhouse scaling, workforce development, and working capital.
Post-expansion projections include:
- 500,000–1,000,000 plantlets annually
- Multi-species production portfolio
- Regional export readiness
- Downstream integration into essential oil and specialty crop supply chains
Positioning at the Intersection of Biotech and Sustainable Agriculture
By combining plant biotechnology, agroforestry integration, and digital traceability, COPI positions the Agaris™ platform as a scalable and investment-grade agricultural solution aligned with ESG, reforestation, and climate-resilient farming initiatives.
“Our vision is to become Southeast Asia’s leading plant biotechnology platform for high-value agroforestry and perfumery crops,” said company leadership. “Through strategic partnerships and responsible scaling, we aim to strengthen plantation productivity while supporting sustainable rural enterprise.”
Investor & Partnership Inquiries
Crown Organogenesis Protocols Inc. (COPI)
Christine Village 4, Brgy. Biga
Tanza 4108, Cavite, Philippines
Email: crownorganogenesisprotocols@gmail.com
Phone: +63 46 418 9530
About Crown Organogenesis Protocols Inc.
Crown Organogenesis Protocols Inc. (COPI) is a Philippine-based plant biotechnology company specializing in organogenesis-driven clonal propagation systems for high-value agroforestry, perfumery, and specialty crops. Through its Agaris™ platform, COPI delivers standardized, traceable, and field-ready elite plantlets for commercial-scale plantation development.